The CSL share price just hit a multi-year low, is it time to buy?

The healthcare giant is suffering a loss of investor confidence.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has dropped more than 20% in the last four months. The ASX healthcare share giant is now down around 30% from its pre-COVID high. It's at a multi-year low.

It's lower today than it was during the worst of the COVID-19 crash in March 2020.

CSL is often seen as one of the highest-quality healthcare businesses in Australia, yet it's experiencing a sell-off.

What's happening with the CSL share price?

The company recently held its annual general meeting (AGM) and it wasn't great news. For example, in CSL Behring, the business is seeing a lower profit margin. Dr Paul McKenzie, the CSL CEO said:

We expect CSL Behring gross margin to return to pre-COVID levels in the medium term. The path to margin recovery however is different to the COVID driven margin decline. The largest contributor to gross margin improvement, [is a] reduction in our cost per litre. The biggest components within cost per litre are donor compensation and direct labour. Cost per litre is around 17% off the peak, so we are making genuine inroads, but there is more to do and it's just going to take some time.

There was also a suggestion that new products and improving yields could help the profit margin.

One of the most important things that investors like to judge a business on is the profit it makes.

CSL has guided that for FY24 it's expecting revenue to grow approximately 9% to 11% at constant currency (meaning the same exchange rates).

The business is projecting that underlying net profit after tax (NPATA) will be between $2.9 billion to $3 billion at constant currency, which would be growth of between 13% to 17%, though the growth rate excludes the one-off gain it made from the sale of property in FY23 of $44 million.

There is also a lot of commentary about the potential for the drug Ozempic to have a positive effect on people with kidney disease and related illnesses. CSL is exposed to this through its Vifor acquisition. As my colleague James Mickleboro reported, investment bank Goldman Sachs recently said:

There is a direct link to CSL through the Vifor segment (potentially a direct earnings impact for a company which sells drugs to the kidney disease/dialysis populations, but also potential consequences for the carrying value of the business itself, which is comprised almost entirely of intangible assets and goodwill).

Time to buy?

Warren Buffett once said that investors should be greedy when investors are fearful and fearful when investors are greedy.

Investors may be overreacting by sending the CSL share price as low as it has gone. There are many products in the CSL portfolio, not just Vifor ones, but it'd be a disappointing use of capital if it turns out that Vifor's potential is not as great as first thought. Though, it's possible that Vifor could do better than the pessimists are thinking.

According to analyst ratings collated by Factset, there are 16 buy ratings on CSL, two hold ratings and one sell rating. That's a very bullish group of analysts.

However, another of Warren Buffett's pieces of investment advice is to stay within your circle of competence. In other words, only invest in what you understand.

ASX biotechnology shares, even as one as big as CSL, isn't an area I can claim to have much expertise about, which is why I'm not a shareholder and I don't often say it's worth looking at. To me, there's always a chance in that industry that a competitor could invent a better treatment, and I wouldn't know how to judge the likelihood of that.

The CSL share price may be an opportunity, but it's not the first thing I'd invest in with $10,000.

Should you invest $1,000 in Mydeal.com.au Limited right now?

Before you buy Mydeal.com.au Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mydeal.com.au Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »